SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea
· Delayed Price · Currency is KRW 93,000
+1,400 (1.53%)
At close: May 30, 2025, 3:30 PM KST
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| New Drugs | 547.60B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| New Drugs Growth | 54.30% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Service | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Service Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Consolidated Adjustment | -594.66B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consolidated Adjustment Growth | 27.97% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States | 667.82B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States Growth | 31.23% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| South Korea | 474.43B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| South Korea Growth | 52.69% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consolidated Adjustment | -594.66B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consolidated Adjustment Growth | 27.97% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cayman Islands | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Netherlands | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Canada | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Japan | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Ireland | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|